METHODS: Longitudinal plasma samples were collected post curative-intent treatment from 36 patients with stage I-IV NSCLC. A personalized, tumor-informed assay was used to detect and quantify ctDNA in plasma samples.
RESULTS: Of the 24 patients with plasma samples available during the MRD window (within 6 months of curative surgery and before adjuvant therapy), ctDNA was detectable in two patients. Patients with ctDNA-positivity during the MRD window were 15 times more likely to recur compared to ctDNA-negative patients (HR: 15.0, 95% CI: 1.0-253.0, p = 0.010). At any time post-curative intent treatment, ctDNA-positivity was associated with significantly poorer recurrence-free survival compared to persistently ctDNA-negative patients (p < 0.0001).
CONCLUSIONS: Our real-world data indicate that longitudinal, personalized, tumor-informed ctDNA monitoring is a valuable tool in patients with NSCLC receiving curative treatment to identify patients at high risk for recurrence.
方法:从36例I-IV期非小细胞肺癌患者治疗后收集纵向血浆样本。一个个性化的,肿瘤知情分析用于检测和定量血浆样品中的ctDNA.
结果:在MRD窗口期间(治愈性手术后6个月内和辅助治疗前)可获得血浆样本的24例患者中,在两名患者中检测到ctDNA。与ctDNA阴性患者相比,MRD窗口中ctDNA阳性患者复发的可能性是ctDNA阴性患者的15倍(HR:15.0,95%CI:1.0-253.0,p=0.010)。在治疗后的任何时间,与持续ctDNA阴性患者相比,ctDNA阳性与无复发生存率显著降低相关(p<0.0001)。
结论:我们的真实世界数据表明,纵向,个性化,在接受治愈性治疗的非小细胞肺癌患者中,肿瘤知情ctDNA监测是一种有价值的工具,可用于识别复发高危患者.